Janux Therapeutics Inc
For the period ended Dec 31, 2024. Filed Feb 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 27, 2025
JANX$12.04-5.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets
(in thousands, except share and par value data)
| December 31, | ||
|---|---|---|
| Assets | 2024 | 2023 |
| Current assets: | ||
| Cash and cash equivalents | $430,605 | $19,205 |
| Short-term investments | 594,568 | 324,823 |
| Prepaid expenses and other current assets | 8,493 | 5,213 |
| Total current assets | 1,033,666 | 349,241 |
| Restricted cash | 816 | 816 |
| Property and equipment, net | 4,864 | 7,003 |
| Operating lease right-of-use assets | 19,286 | 20,838 |
| Other long-term assets | 2,884 | 2,509 |
| Total assets | $1,061,516 | $380,407 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $4,026 | $2,424 |
| Accrued expenses | 11,684 | 7,387 |
| Current portion of deferred revenue | — | 1,705 |
| Current portion of operating lease liabilities | 1,749 | 1,517 |
| Total current liabilities | 17,459 | 13,033 |
| Operating lease liabilities, net of current portion | 21,276 | 23,025 |
| Total liabilities | 38,735 | 36,058 |
| Commitments and contingencies (Note 3) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value; authorized shares – 10,000,000 at December 31, 2024 and 2023, respectively; no shares issued and outstanding at December 31, 2024 and 2023 | — | — |
| Common stock, $0.001 par value; authorized shares – 200,000,000 at December 31, 2024 and 2023, respectively; issued shares – 59,064,606 and 46,262,759 at December 31, 2024 and 2023, respectively; outstanding shares – 59,064,606 and 46,252,440 at December 31, 2024 and 2023, respectively | 59 | 46 |
| Additional paid-in capital | 1,258,316 | 512,401 |
| Accumulated other comprehensive income | 2,163 | 665 |
| Accumulated deficit | (237,757) | (168,763) |
| Total stockholders’ equity | 1,022,781 | 344,349 |
| Total liabilities and stockholders’ equity | $1,061,516 | $380,407 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.